Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

January 13, 2021 Auto Bot regulatory 0

Shots:

  • Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
  • The US FDA granted PR to the therapy, allowing the agency to take action on NDA within 6mos. of acceptance compared to 10mos. under standard review
  • Finerenone is an investigational, non-steroidal, selective MRA and has showed a reduction in harmful effects of MR overactivation. The therapy has demonstrated positive kidney and CV outcomes in patients with CKD and T2D

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: Market Screener

The post Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D first appeared on PharmaShots.